A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Rituximab; Vincristine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2024 Planned End Date changed from 31 Mar 2025 to 1 Mar 2026.
- 16 Apr 2024 Planned primary completion date changed from 31 Mar 2025 to 1 Mar 2026.
- 04 Apr 2023 Status changed from suspended to recruiting.